AZ, Junshi Part Ways Amid China IO Commercial Struggle
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
You may also be interested in...
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.